Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1520)	9/2/2004 1:57:38 PM
From: Icebrg	Respond to of 1826

MGI Pharma upgraded to "outperform" Thursday, September 02, 2004 12:18:04 PM ET Bear Stearns NEW YORK, September 2 (New Ratings) - Analysts at Bear Stearns upgrade MGI Pharma (MOGN.NAS) from "peer perform" to "outperform." The target price is set to $38.

To: Icebrg who wrote (1520)	9/20/2004 1:59:54 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma "outperform" [The guys at Robert Baird have a habit of saying the same thing over and over again. That there has been a increase in the clinical risk after MOGN's sweep through the biotech sector seems more or less self-evident. But maybe the note itself contains more meat]. Monday, September 20, 2004 9:39:57 AM ET Robert W. Baird NEW YORK, September 20 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma (MOGN.NAS). The target price is set to $35. In a research note published this morning, the analysts mention that MGI Pharma’s product pipeline has expanded substantially, following the company's recent acquisitions. The company is expected to have five separate compounds in pivotal trials by mid-2005, the analysts add. The acquisitions have, however, also raised the clinical risk associated with MGI Pharma, Robert W Baird says.